N/A N=828 Multiple Areas of Pain (MAP)
Chronic Pain
Primary: Multi-site Pain Index — 0.52 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=38 Bioequivalence of Two Lispro Formulations
Healthy Volunteers
Primary: Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration…
N/A N=268 Nurse Reduction of Pulled Elbow
Radial Head Subluxation
Primary: Proportion of Patients With Successful Reduction of Radial Head Subluxation by Nurse, Compared With Physician Controls — 84.7; 96.7 percentage of patients reduced
N/A N=42 Treating Sleep Problems in VA Adult Day Health Care
Insomnia · Sleep Disorders
Primary: Sleep Efficiency — 86.6; 83.3 percentage of time in bed spent asleep — p=.04
Phase 2 N=41 A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Percentage of Participants Who Are Progression-free (PFS) at 6 Months — 59.0 percentage of participants
N/A N=1,000 Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study
Irregular Menstrual Cycle
Primary: Percentage of Patients Reporting a Regular Cycle — 96.7 percentage of participants
Phase 3 N=663 Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Time — 4.27; 2.60 months
Phase 4 N=40 Duloxetine in Osteoarthritis (OA) Pain
Osteoarthritis
Primary: Change in Brain Gray Matter Volume — -0.34; -0.92 percentage of change
Phase 1 N=236 Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer
Breast Cancer · Fatigue
Primary: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization — 6.96; 8.33 units on a scale — p=0.1815
Phase 4 N=300 Effectiveness of Topical Antibiotic Prophylaxis in Inguinal Hernia Repair
Inguinal Hernia
Primary: Rate of Post-operative Infection
Phase 3 N=1,253 A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
Non-Small Cell Lung Cancer
Primary: Overall Survival — 10.5; 9.1 months
Phase 2 N=280 A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 5.6; 7.2; 5.4; 5.6 months — p=0.1318
Phase 4 N=47 Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
Hypertension
Primary: Sympathetic Nerve Activity — 46; 40; 49; 42 bursts/min
Phase 2 N=24 Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Metabolic Syndrome X
Primary: Triglycerides Levels at Week 12 — 210.6; 235.8 mg/dL — p=0.131
Phase 2 N=13 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee — 0 percentage of participants